 |
13 Diseases |  |
1 Trial |
|
1 Trial |  |
12 News |  |
- | Journal: Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. (Pubmed Central) - Apr 13, 2022
Immune checkpoint inhibitors (anti-PD-1/ anti-CTLA-4) and anti-cancer vaccines (NeuVax, Muc-1, AVX901, INO-1400 and CEA), either alone or in combination with other therapies have created new paradigm in therapeutic world. In this review, we highlighted the current immunotherapeutic aspects and their ongoing trials towards the better treatment regimen for BC.
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-1400 / Inovio, INO-1401 / Inovio
Clinical, P1 data, Journal, PD(L)-1 Biomarker, IO biomarker: Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. (Pubmed Central) - Jan 12, 2022
In this review, we highlighted the current immunotherapeutic aspects and their ongoing trials towards the better treatment regimen for BC. Plasmid DNA-encoded hTERT/IL-12 DNA immunotherapy was well-tolerated, immune responses were noted across all tumor types, and a specific CD8+ phenotype increased by the immunotherapy was significantly correlated with survival in patients with pancreatic cancer.
- | INO-1400 / Inovio, Syncon vaccines (H1+H5) / Inovio
Journal, IO Biomarker: Novel Synthetic DNA Immunogens Targeting Latent Expressed Antigens of Epstein-Barr Virus Elicit Potent Cellular Responses and Inhibit Tumor Growth. (Pubmed Central) - May 30, 2019
LMP2Avax was able to drive immunity that impacted EBV-antigen-positive tumor growth. These studies suggest that engineered EBV latent protein vaccines deserve additional study as potential agents for immunotherapy of EBV-driven cancers.
- | Trial completion, Combination therapy, Surgery: hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (clinicaltrials.gov) - Nov 19, 2018
P1, N=93, Completed, Sponsor: Inovio Pharmaceuticals
These studies suggest that engineered EBV latent protein vaccines deserve additional study as potential agents for immunotherapy of EBV-driven cancers. Active, not recruiting --> Completed
- || Enrollment closed, Combination therapy, Surgery: hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (clinicaltrials.gov) - Mar 13, 2018
P1, N=93, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Enrollment change, Combination therapy, Surgery: hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (clinicaltrials.gov) - Nov 24, 2017
P1, N=90, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting N=54 --> 90
- ||| New P1 trial, Combination therapy, Surgery: hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (clinicaltrials.gov) - Nov 8, 2016
P1, N=54, Recruiting, Sponsor: Inovio Pharmaceuticals
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-1400 / Inovio
Trial primary completion date, Combination therapy, Surgery: Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers (clinicaltrials.gov) - Jun 16, 2016
P1, N=54, Recruiting, Sponsor: Inovio Pharmaceuticals
N=54 --> 90 Trial primary completion date: Dec 2016 --> Dec 2017
- rocakinogene sifuplasmid (INO-9012) / Inovio, INO-1400 / Inovio
New P1 trial, Combination therapy, Surgery: Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers (clinicaltrials.gov) - Dec 30, 2014
P1, N=54, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania